Status:

COMPLETED

Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms

Lead Sponsor:

Innovative Medical

Conditions:

Dry Eye

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

To evaluate the efficacy, safety and tolerability of a combination of Optive® Artificial Tears with Restasis®.The primary hypothesis is that the Ocular Surface Disease Index (OSDI) score and symptoms ...

Eligibility Criteria

Inclusion

  • · Males or females \> 18 years old
  • Patients currently taking Restasis® for at least 3 months in duration and using artificial tears as needed for dry eye.
  • Likely to complete all study visits and able to provide informed consent

Exclusion

  • · Patients using Restasis® for less than 3 months.
  • Known contraindications to any study medication or ingredients
  • Female of child bearing potential not using reliable methods of birth control, or pregnant or lactating females.
  • Other active uncontrolled ocular diseases or uncontrolled systemic disease

Key Trial Info

Start Date :

November 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 1 2008

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT00405457

Start Date

November 1 2006

End Date

January 1 2008

Last Update

February 22 2010

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Minnesota Eye Consultants

Minneapolis, Minnesota, United States, 55404